Nicola Heffron
Vertrieb & Marketing bei ALEXION PHARMACEUTICALS, INC.
Vermögen: 108 155 $ am 30.04.2024
Profil
Nicola Heffron is a professional with experience in the pharmaceutical industry.
She is currently the Senior VP, Head-Global Marketing & Market Access at Alexion Pharmaceuticals, Inc. Her former positions include Head-Global Marketing at Celgene Corp.
in 2018, Chief Commercial Officer at bluebird bio, Inc. from 2020 to 2021, and Chief Operating Officer at 2seventy Bio, Inc. from 2021 to 2023.
Ms. Heffron holds an MBA from the University of Warwick.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0,05% | 13.04.2023 | 25 211 ( 0,05% ) | 108 155 $ | 30.04.2024 |
Aktive Positionen von Nicola Heffron
| Unternehmen | Position | Beginn |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Vertrieb & Marketing | 01.04.2023 |
Ehemalige bekannte Positionen von Nicola Heffron
| Unternehmen | Position | Ende |
|---|---|---|
| 2SEVENTY BIO, INC. | Geschäftsführer | 10.03.2023 |
| CELGENE | Vertrieb & Marketing | 01.09.2018 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Ausbildung von Nicola Heffron
| University of Warwick | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| 2SEVENTY BIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
